Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Convertible Debt (2018 - 2022)

Ligand Pharmaceuticals' Convertible Debt history spans 8 years, with the latest figure at $176.5 million for Q1 2022.

  • For Q1 2022, Convertible Debt fell 49.89% year-over-year to $176.5 million; the TTM value through Mar 2022 reached $176.5 million, down 49.89%, while the annual FY2021 figure was $320.7 million, 27.49% down from the prior year.
  • Convertible Debt for Q1 2022 was $176.5 million at Ligand Pharmaceuticals, down from $320.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $639.0 million in Q4 2019 and bottomed at $176.5 million in Q1 2022.
  • The 5-year median for Convertible Debt is $452.3 million (2020), against an average of $474.6 million.
  • The largest annual shift saw Convertible Debt grew 4.77% in 2019 before it tumbled 49.89% in 2022.
  • A 5-year view of Convertible Debt shows it stood at $609.9 million in 2018, then increased by 4.77% to $639.0 million in 2019, then crashed by 30.78% to $442.3 million in 2020, then fell by 27.49% to $320.7 million in 2021, then plummeted by 44.95% to $176.5 million in 2022.
  • Per Business Quant, the three most recent readings for LGND's Convertible Debt are $176.5 million (Q1 2022), $320.7 million (Q4 2021), and $316.9 million (Q3 2021).